Printer Friendly

Zymeworks Appoints Computational Antibody Design Expert Dr. Bruce Tidor to its Scientific Advisory Board.

VANCOUVER, British Columbia -- Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Dr. Bruce Tidor, Professor in the Departments of Biological Engineering and of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology (MIT), to its scientific advisory board.

"Dr. Tidor is renowned in academia and industry for his use of leading-edge computational methodologies to understand and engineer protein therapeutics," says Dr. Ali Tehrani, President and CEO of Zymeworks. "His unique cross-disciplinary blend of expertise and vision in modeling and biochemistry will be invaluable to Zymeworks' ongoing technology refinement in rational protein optimization and engineering."

Dr. Bruce Tidor is Professor of Biological Engineering and Computer Science and is a member of the Computer Science and Artificial Intelligence Laboratory at MIT. With over 100 peer-reviewed publications, Dr. Tidor's prolific research centers on the use of molecular modeling and computation to understand protein and nucleic acid structures, functions, and interactions. One of his recent highly regarded studies described the use of rational design to optimize monoclonal antibodies Avastin[R] and Erbitux[R], leading to the opportunity to use similar approaches to develop second-generation protein therapeutics. Dr. Tidor graduated summa cum laude with an A.B. in Chemistry and Physics from Harvard College, earned a M.Sc. in Biochemistry at Oxford University's Wolfson College as a Marshall Scholar, and received his Ph.D. in Biophysics from Harvard. He was a Whitehead Fellow at the Whitehead Institute for Biomedical Research and currently serves as the founding co-Director of MIT's Computational and Systems Biology Initiative.

About Zymeworks Inc.

Zymeworks is a computational biotechnology company researching and developing next-generation protein therapeutics. Zymeworks leverages proprietary insight into structure-function relationships generated by the ZymeCAD[TM] platform to optimize the efficacy and potency of protein therapeutics. Zymeworks is focused on developing a biotherapeutics pipeline through strategic collaborations and internal research programs. More information on Zymeworks can be found at
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Oct 2, 2009
Previous Article:Research and Markets: Manufacturing Applications Investment in Sweden to 2014 where Revenue is Expected to Reach $308.2.
Next Article:Dapagliflozin Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled...

Related Articles
Alfacell announces new research collaboration to develop next-generation targeted therapies for cancer.
Adimab Announces Scientific Advisory Board Members.
Zymeworks Appoints Key Industry Leaders to its Scientific Advisory Board.
Zymeworks Appoints Antibody and Drug Development Expert Dr. Paul J. Carter to its Scientific Advisory Board.
Acetylon Pharmaceuticals raises $7.25 million.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters